Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRUM trial of full-spectrum cannabis extract for refractory epilepsy associated with tuberous sclerosis complex
2024-520171-27-00Phase 3Authorised
- Sponsor
- Oils4Cure
- Start
- Jan 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of YCJ-01, cannabidiol and dronabinol in tuberous sclerosis complex (TSC) (2 arms), sponsored by Oils4Cure. Primary endpoints: Change in monthly seizure count from baseline after YCJ-01 initiation and Safety and tolerability. Planned start Jan 2025; status: authorised.
02
Drugs
YCJ-01cannabidioldronabinol
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2024-520171-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520171-27-00.